Cetuximab, a chimeric anti-EGFR IgG1 is approved by the FDA for HNSCC patients, which binds to EGFR with high affinity, prevents the activation of downstream signaling pathways and also induces antibody-dependent cellular toxicity [13–15]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.